Skip to main content

Outage notice:

Due to the global information outage that occurred Friday, Quest is taking swift action to respond, recover and restore our operations. Our Patient Services are operating with reduced capacity so you may experience longer wait and service times. Our Customer Contact teams are currently unavailable. We appreciate your patience as we work toward returning to normal operations. 


Accessibility for you and your patients. 

Blood-based biomarker tests offer unparalleled accessibility and convenience, enabling a broader population to access early diagnosis and monitoring for AD. Quest is one of the largest national labs with a network of approximately 2,100 Patient Service Center locations. That means your patients can get their blood drawn where it's convenient for them, ultimately streamlining the diagnostic process. AD-Detect Amyloid Beta 42/40 Ratio can pave the way to help determine if more extensive testing—like CSF or PET—is necessary.



Establish a baseline and monitor your patients throughout their journey.

Identify AD risk early and continually monitor your patient's amyloid beta biomarkers over time. Our enhanced reporting provides Aβ42/40 ratio values from current and 5 past results all in one table.


The Emerging Role of Blood-based Biomarkers in Alzheimer's Disease 

Hear experts discuss the current opportunities and challenges in diagnosing AD, the emerging role, of blood­based biomarkers (e.g., P-tau, Aβ42/Aβ40, Nfl) in screening and monitoring, and exploring new treatments and diagnostics pathways to help inform patient care. 


See how we are actively working to empower you with insights to drive care for patients with dementia 

View full portfolio


1. Alzheimer’s Association. 2023 Alzheimer’s disease facts and figures. Accessed October 3, 2023.

2. Pascual-Lucas M, Allué JA, Sarasa L, et al. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline. Alzheimer’s Research & Therapy. 2023;15(1). doi:

3. Cummings J, Lee G, Zhong K, et al. Alzheimer's disease drug development pipeline: 2021. Alzheimer's Dement (NY). 2021; 7(1):e12179. doi:1 0.1 002/trc2.12179.